Literature DB >> 33971144

The Association Between Lung Hyperinflation and Coronary Artery Disease in Smokers.

Divay Chandra1, Aman Gupta1, Gregory L Kinney2, Carl R Fuhrman3, Joseph K Leader3, Alejandro A Diaz4, Jessica Bon1, R Graham Barr5, George Washko4, Matthew Budoff6, John Hokanson2, Frank C Sciurba7.   

Abstract

BACKGROUND: Smokers manifest varied phenotypes of pulmonary impairment. RESEARCH QUESTION: Which pulmonary phenotypes are associated with coronary artery disease (CAD) in smokers? STUDY DESIGN AND METHODS: We analyzed data from the University of Pittsburgh COPD Specialized Center for Clinically Oriented Research (SCCOR) cohort (n = 481) and the Genetic Epidemiology of COPD (COPDGene) cohort (n = 2,580). Participants were current and former smokers with > 10 pack-years of tobacco exposure. Data from the two cohorts were analyzed separately because of methodologic differences. Lung hyperinflation was assessed by plethysmography in the SCCOR cohort and by inspiratory and expiratory CT scan lung volumes in the COPDGene cohort. Subclinical CAD was assessed as the coronary artery calcium score, whereas clinical CAD was defined as a self-reported history of CAD or myocardial infarction (MI). Analyses were performed in all smokers and then repeated in those with airflow obstruction (FEV1 to FVC ratio, < 0.70).
RESULTS: Pulmonary phenotypes, including airflow limitation, emphysema, lung hyperinflation, diffusion capacity, and radiographic measures of airway remodeling, showed weak to moderate correlations (r < 0.7) with each other. In multivariate models adjusted for pulmonary phenotypes and CAD risk factors, lung hyperinflation was the only phenotype associated with calcium score, history of clinical CAD, or history of MI (per 0.2 higher expiratory and inspiratory CT scan lung volume; coronary calcium: OR, 1.2; 95% CI, 1.1-1.5; P = .02; clinical CAD: OR, 1.6; 95% CI, 1.1-2.3; P = .01; and MI in COPDGene: OR, 1.7; 95% CI, 1.0-2.8; P = .05). FEV1 and emphysema were associated with increased risk of CAD (P < .05) in models adjusted for CAD risk factors; however, these associations were attenuated on adjusting for lung hyperinflation. Results were the same in those with airflow obstruction and were present in both cohorts.
INTERPRETATION: Lung hyperinflation is associated strongly with clinical and subclinical CAD in smokers, including those with airflow obstruction. After lung hyperinflation was accounted for, FEV1 and emphysema no longer were associated with CAD. Subsequent studies should consider measuring lung hyperinflation and examining its mechanistic role in CAD in current and former smokers.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  COPD; coronary artery disease; lung hyperinflation; smoking

Mesh:

Year:  2021        PMID: 33971144      PMCID: PMC8449003          DOI: 10.1016/j.chest.2021.04.066

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   10.262


  39 in total

1.  Automated detection and quantitative assessment of pulmonary airways depicted on CT images.

Authors:  Bin Zheng; Joseph K Leader; Jessica M McMurray; Sang Cheol Park; Carl R Fuhrman; David Gur; Frank C Sciurba
Journal:  Med Phys       Date:  2007-07       Impact factor: 4.071

2.  Subclinical atherosclerosis, airflow obstruction and emphysema: the MESA Lung Study.

Authors:  R G Barr; F S Ahmed; J J Carr; E A Hoffman; R Jiang; S M Kawut; K Watson
Journal:  Eur Respir J       Date:  2011-10-27       Impact factor: 16.671

3.  A rapid food screener to assess fat and fruit and vegetable intake.

Authors:  G Block; C Gillespie; E H Rosenbaum; C Jenson
Journal:  Am J Prev Med       Date:  2000-05       Impact factor: 5.043

4.  Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort.

Authors:  Jessica Bon; Carl R Fuhrman; Joel L Weissfeld; Steven R Duncan; Robert A Branch; Chung-Chou H Chang; Yingze Zhang; Joseph K Leader; David Gur; Susan L Greenspan; Frank C Sciurba
Journal:  Am J Respir Crit Care Med       Date:  2010-10-08       Impact factor: 21.405

5.  Hyperinflation is associated with lower sleep efficiency in COPD with co-existent obstructive sleep apnea.

Authors:  Jeff S Kwon; Lisa F Wolfe; Brandon S Lu; Ravi Kalhan
Journal:  COPD       Date:  2009-12       Impact factor: 2.409

6.  Reliability analysis of visual ranking of coronary artery calcification on low-dose CT of the thorax for lung cancer screening: comparison with ECG-gated calcium scoring CT.

Authors:  Yoon Kyung Kim; Yon Mi Sung; So Hyun Cho; Young Nam Park; Hye-Young Choi
Journal:  Int J Cardiovasc Imaging       Date:  2014-08-02       Impact factor: 2.357

7.  Collapsibility of lung volume by paired inspiratory and expiratory CT scans: correlations with lung function and mean lung density.

Authors:  Tsuneo Yamashiro; Shin Matsuoka; Brian J Bartholmai; Raúl San José Estépar; James C Ross; Alejandro Diaz; Sadayuki Murayama; Edwin K Silverman; Hiroto Hatabu; George R Washko
Journal:  Acad Radiol       Date:  2010-01-12       Impact factor: 3.173

8.  Mortality associated with respiratory function and symptoms in advanced age. The Framingham Study.

Authors:  P D Sorlie; W B Kannel; G O'Connor
Journal:  Am Rev Respir Dis       Date:  1989-08

9.  Visual Estimate of Coronary Artery Calcium Predicts Cardiovascular Disease in COPD.

Authors:  Surya P Bhatt; Ella A Kazerooni; John D Newell; John E Hokanson; Matthew J Budoff; Chandra A Dass; Carlos H Martinez; Sandeep Bodduluri; Francine L Jacobson; Andrew Yen; Mark T Dransfield; Carl Fuhrman; Hrudaya Nath
Journal:  Chest       Date:  2018-06-08       Impact factor: 9.410

10.  Centrilobular emphysema and coronary artery calcification: mediation analysis in the SPIROMICS cohort.

Authors:  Surya P Bhatt; Hrudaya P Nath; Young-Il Kim; Rekha Ramachandran; Jubal R Watts; Nina L J Terry; Sushil Sonavane; Swati P Deshmane; Prescott G Woodruff; Elizabeth C Oelsner; Sandeep Bodduluri; MeiLan K Han; Wassim W Labaki; J Michael Wells; Fernando J Martinez; R Graham Barr; Mark T Dransfield
Journal:  Respir Res       Date:  2018-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.